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ABSTRACT 
OPTIMIZING ANESTHESIA PROVIDERS’ TIMING OF ADMINISTRATION OF 
DEXAMETHASONE FOR THE PREVENTION OF POST-OPERATIVE 
 NAUSEA AND VOMITING: TRANSLATING CLINICAL  
GUIDELINES INTO PRACTICE 
by Tanner Young Mixon 
December 2016 
Research has shown that post-operative nausea and vomiting (PONV) is a 
significant contributing factor to extended recovery times and unwanted hospital 
admissions following ambulatory surgery. The purpose of this DNP project was to assess 
current practice regarding administration of dexamethasone for the prevention of PONV, 
provide information based on best practice guidelines, and assess willingness to change 
practice based on the guidelines set forth by the Society for Ambulatory Anesthesia 
(SAMBA). Administration of dexamethasone is aimed at decreasing the incidence of 
PONV, optimizing PACU times, and increasing patient satisfaction regarding 
perioperative care. 
An electronic presentation and survey were emailed to members of the 
Mississippi Association of Nurse Anesthetists (MANA) for the purpose of educating 
anesthesia providers about current evidence guiding PONV prevention as well as assess 
current practice of members. Results were analyzed using descriptive statistics. The 
majority of CRNAs surveyed were found to administer dexamethasone in accordance 
with the guidelines set forth by SAMBA. It was also found that the CRNAs surveyed 
 iii 
displayed a willingness to change their current practice when provided with an evidence-
based alternative aimed at optimizing patient outcomes. 
The results in combination with the guidelines set forth by the Society for 
Ambulatory Anesthesia were used to make recommendations meant to improve patient 
outcomes following surgery. These recommendations were disseminated to members of 
The Mississippi Association of Nurse Anesthetists (MANA) through email as well as the 
MANA website. 
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CHAPTER I – INTRODUCTION 
Statement of Problem 
Post-operative nausea and vomiting (PONV) is a very real concern for both 
patients and healthcare providers in the ambulatory surgical setting. According to 
Butterworth, Mackey, and Wasnick (2013), 1 in every 4 patients will develop post-
operative nausea and vomiting (PONV) if not prophylactically treated with an anti-
emetic. Multiple studies have shown the significant role PONV plays in recovery from 
surgery. Researchers found that PONV is a significant contributing factor to extended 
recovery times and unwanted hospital admissions following ambulatory surgery (Fortier, 
Chung, & Su, 1998). A follow up study in 2013 found similar results linking PONV to 
unwanted hospital admissions following day surgery (Whippey et al., 2013). Research 
has shown that avoiding PONV outranks even pain among patients asked about their 
concerns following surgery (Eberhart, Morin, Wulf, & Geldner, 2002; Gan & Habib, 
2016; Lee, Gin, Lau, Dip, & Ng, 2004). PONV is stressful and disruptive to the patient 
on a personal level, as well as costly to both the patient and facility. According to Gan 
and Habib (2016), patients are willing to spend between $73 and $100 of their own 
money to avoid PONV. 
Statement of Purpose 
While there are a number of clinical tools and guidelines available to assess the 
risk and guide treatment of post-operative nausea and vomiting, research suggests 
varying practices amongst anesthesia providers in relation to pretreating a patient at risk 
for post-operative nausea and vomiting (Smith, Smith, & Smith, 2012). Further, it has 
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been demonstrated that the timing of administration of dexamethasone can play a 
significant role in preventing PONV (Zou, Jiang, Xiao, & Zhou, 2014). 
The purpose of this DNP project was to assess current practice regarding 
administration of dexamethasone for the prevention of PONV, provide information based 
on best practice guidelines, and assess willingness to change practice based on the 
guidelines set forth by The Society for Ambulatory Anesthesia (SAMBA). The results in 
combination with the guidelines set forth by SAMBA (Gan et al., 2014) were used to 
make recommendations meant to improve patient outcomes following surgery. 
Administration of dexamethasone is aimed at decreasing the incidence of PONV 
postoperatively, optimizing PACU times and increasing patient satisfaction regarding 
perioperative care. 
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CHAPTER II – REVIEW OF LITERATURE 
Current Guidelines 
Gan et al. (2014) formed a multidisciplinary panel under the guidance of The 
Society for Ambulatory Anesthesia for the purpose of setting general guidelines directing 
the use of antiemetics for the prevention of PONV. The panel determined a single 4 to 
5mg dose of dexamethasone at or before induction effectively reduces PONV as well as 
increases the quality of recovery after being discharged (Gan et al., 2014). In addition to 
directing the administration of dexamethasone, the guidelines suggest a set of patient-
specific risk factors to help determine which patients are best suited for prophylactic 
treatment of PONV. Significant individual risk factors include being female, less than 50 
years old, a history of PONV or motion sickness, and being a non-smoker as can be 
found in Table 1. The presence of one or more risk factors increases the risk of PONV 
(Gan et al., 2014). 
Table 1 PONV Risk Factors 
Clinically Significant Risk Factors Contributing to PONV 
 Female 
 History of PONV or motion sickness 
 Nonsmoker 
 Age less than 50 years old 
 General anesthesia versus regional block 
 Use of anesthetic gas (volatile and nitrous oxide) 
 Use of opioids for postoperative pain control 
 Duration of anesthetic 
 Type of surgery (abdominal and gynecological) 
 
Adapted from the guidelines set forth by Gan et al. (2014) 
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Gan and Habib (2016), who helped author the consensus guidelines published in 
2014, recently published a book guiding the treatment of PONV. The authors continue to 
recommend the administration of a single 4-5mg dose of dexamethasone before or 
immediately after induction. It is noted that perineal burning, a well-known side effect of 
IV dexamethasone, limits its use pre-induction. Gan and Habib (2016) suggest the same 
level of PONV prophylaxis exists if dexamethasone is given immediately after induction. 
Dexamethasone induced hyperglycemia is seen as one of the only possible sources of 
postoperative complications, due to an increased risk for post-operative infection and 
delayed wound healing.  The authors offer that a single dose approach, and using the 
suggested 4-5mg versus the popular dose of 8mg mitigates the risk of these complications 
(Gan & Habib, 2016). 
Tarantino et al. (2015) performed a randomized, double-blind, placebo-controlled 
trial over two years. Patients were assessed for the presence of PONV for 48 hours 
following surgery. The researchers found there to be a 28% reduction in absolute risk of 
PONV when patients were given a single 8mg dose of dexamethasone preoperatively 
compared to a placebo. Though the 8mg dose is associated with an increased blood 
glucose level post-operatively, a recent study (Doyle, 2015) suggests 4mg to be as 
effective at preventing PONV while allowing for the possibility of a dose dependent 
decrease in the hyperglycemic response. In a similar study, Azeem, Ullha, Nasim, and 
Cheema (2015) considered patients undergoing laparoscopic cholecystectomy. Patients 
were monitored 24 hours following surgery for the presence of PONV. Results showed 
PONV in 17% of those receiving dexamethasone and 53% of those receiving a placebo. 
It was noted that no adverse effects were observed. Eftekharian and Roozbahany (2011) 
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and Zou et al. (2014) both reported similar findings, noting dexamethasone was most 
affective at reducing the incidence of PONV when given at or before induction of 
anesthesia. 
Patient Significance 
PONV is a significant factor contributing to unwanted hospital admissions 
following what were scheduled as ambulatory surgeries (Fortier et al., 1998; Whippey et 
al., 2013). Gan and Habib (2016) also point to PONV as a significant contributor to 
extended post anesthesia care unit (PACU) stays as well as unwanted hospital 
admissions, noting that each occurrence of emesis adds an estimated 20 minutes to the 
PACU stay. While an exact number is hard to calculate, it is estimated that extra costs 
related to PONV and post-discharge nausea and vomiting (PDNV) amount to several 
million US dollars annually (Gan & Habib, 2016). Unexpected overnight admissions to 
the hospital can lead to further disruption for the patient in regards to their time and 
recovery. Each extra day spent in the hospital increases the chance of infection by up to 
1.37% (Hassan, Tuckman, Patrick, Kountz, & Kohn, 2010). According to a study by De 
Lissovoy et al. (2009) looking at 723,490 patients hospitalized due to surgery, a single 
surgical site infection extended the length of hospital stay by an average of 9.7 days. 
Extended recovery times and increased risk of unwanted hospital admission following 
ambulatory surgery can mean time away from work and lost wages. This also increases 
the time it takes a patient to return to their normal level of activity (Gan & Habib, 2016). 
While unexpected admissions and infection rates are straightforward to measure, patient 
satisfaction is more subjective in nature. 
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Odom-Forren et al. (2014) reported in a 2014 study that patients exhibiting PONV 
and PDNV reported a decreased quality of life until symptoms resolved. The authors also 
found PONV and PDNV to affect the patient’s ability to eat and drink, perform normal 
daily activities, and sleep for up to a week after discharge following ambulatory surgery. 
Patient satisfaction with their treatment was found to be negatively affected by the 
presence of PONV and PDNV (Odom-Forren et al., 2014). White et al. (2008) also 
reported that PONV interfered with a patient’s level of function in regards to their 
appetite and ability to sleep, both of which play a vital role in a patient’s recovery from 
surgery. In a study by Eberhart et al. (2002), patients were asked questions related to their 
concerns regarding recovery from surgery. The authors concluded PONV ranked highest, 
even outranking pain, when it came to what the patients were most worried about in the 
immediate postoperative period (Eberhart et al., 2002). Gan and Habib (2016) report 
similar findings, stating patients fear PONV at a higher rate than pain and shivering. 
Facility Significance 
Fortier et al. (1998) determined PONV to be a significant factor contributing to 
14.4% of unwanted hospital admissions following ambulatory surgery. A more recent 
study (Whippey et al., 2013) found similar results further pointing to PONV as an 
important and modifiable risk factor relating to delayed recovery from surgery. As stated 
before, each occurrence of emesis can increase PACU stay times by about 20 minutes 
(Gan & Habib, 2016). According to Raft, Millet, and Meistelman (2014), in 2012 the 
average cost for a stay in the PACU was estimated to be $12 per minute, which would 
equal $240 per episode of emesis. Another study conducted by Habib, Chen, Taquchi, 
Hu, and Gan (2006) linked emesis to significantly increased use of resources, requiring 
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the nurse’s full attention and the use of rescue anti-emetics, as well as increased PACU 
times up to 25 minutes per episode and associated costs of $138. In contrast, the 
pharmacy at a trauma center located in Mississippi indicated that the cost of a single 4mg 
vial of dexamethasone cost around $2.50. Unexpected hospital admissions can also 
contribute significantly to cost for facilities considering that as of 2014, the average cost 
of one inpatient day at a hospital in Mississippi was $1351 (The Henry J. Kaiser Family 
Foundation, n.d.). According to Zimlichman et al. (2013), the cost of a single surgical site 
infection in 2012 was around $20,000 and totaled $3.3 billion in the US for the year, 
reflecting what De Lissovoy et al. (2009) found in an earlier study looking at how 
surgical site infections affect the cost of healthcare.  
Patient satisfaction scores can be factored into reimbursement rates, showing the 
importance of optimizing a patient’s perioperative experience. Hocking, Weightman, 
Smith, Gibbs, and Sherrard (2013) reported PONV as the source of 9% of the variance in 
patient’s perceptions of the quality of anesthesia provided to them. In a study analyzing 
perioperative factors affecting HCAHPS responses of 2,758 surgical patients, Maher et 
al. (2015) found pre-operative and post-operative experiences to be the largest 
contributing factors to how patients ranked their encounter, lending to the importance of 
the post-operative experience and its effect on patient satisfaction scores. Eberhart et al. 
(2002) determined PONV to be the most significant concern for patients in the immediate 
postoperative period, suggesting anesthesia providers pay close attention to the 
prevention of PONV. White, O’Hara, Roberson, Wender, and Candiotti (2008) found 
PONV led to a reduction in appetite as well as sleep following surgery, further pointing 
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to the importance of preventing PONV in relation to patient outcomes and patient 
satisfaction scores as determinants of reimbursement. 
Summation of the Literature 
Based on the review of current literature, there exists a large body of evidence in 
support of using dexamethasone as an antiemetic. Consensus guidelines (Gan et al., 
2014) point to dexamethasone as an effective and inexpensive prophylactic treatment for 
PONV. Further, it is a medication with few side effects which can be minimized through 
optimal dosage and timing of administration (Gan & Habib, 2016).  
PONV is an important factor related to patient recovery. Both White et al. (2008) 
and Odom-Forren et al. (2014) found PONV and PDNV to negatively affect a patient’s 
post-operative experience and delay the return to normal day-to-day activities, pointing to 
prevention of PONV as an important part of recovery from surgery. Post-operative 
experience and PONV also plays an important role in patient satisfaction scores (Maher 
et al., 2015), which can negatively affect reimbursement based on patients’ perception of 
the quality of anesthesia provided (Hocking et al., 2013). PONV can also directly affect 
cost of care through increased PACU times (Gan & Habib, 2016) and increased resource 
usage (Habib et al., 2006). Each episode of emesis from PONV in the PACU has been 
estimated to cost up to $240 dollars (Raft et al., 2014). 
Conclusion 
While each of the studies above presents different levels of effectiveness and 
significance, they all suggest that there is potential value in the use of dexamethasone as a 
cost effective, safe, and reliable prophylactic treatment for post-operative nausea and 
vomiting aimed at improving patient outcomes. More importantly, the aforementioned 
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studies support the current guidelines set forth by the Society for Ambulatory Anesthesia 
(Gan et al., 2014). 
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CHAPTER III  - METHODOLOGY 
Target Outcomes 
The planned outcomes of this DNP project were to: 
1. Assess current practice among CRNAs related to the use of dexamethasone 
for preventing PONV and 
2. Provide an educational presentation of the guidelines set forth by the Society 
for Ambulatory Anesthesia and supporting evidence regarding the prevention 
of PONV using dexamethasone and 
3. Assess CRNA willingness to change current practice based on the evidence 
presented. 
Theoretical Framework 
The focus of this project follows the goals outlined by the Model for Change to 
Evidence-Based Practice as proposed by Rosswurm and Larrabee (1999). This theoretical 
framework describes a process that calls for assessing whether there is a need for a 
change in practice, linking the need with specific interventions and patient outcomes, 
compiling evidence, creating a plan for changing the current practice, implementing and 
evaluating the change, then merging the change with current standards so as to maintain 
the new standard as proposed by the findings of the study (Rosswurm & Larrabee, 1999). 
The proposed theoretical framework provides a tested and trusted guide for evaluating 
and implementing change in practice if indicated. It also provides for the future 
implementation of the aforementioned guidelines if indicated by the findings of this DNP 
project. Due to the limited time frame available, this capstone project utilized the first 
four steps outlined by Rosswurm and Larrabee (1999): assessing the need for change, 
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linking the need with specific interventions and outcomes, compiling the evidence, and 
creating a plan for changing the current practice. 
Target Population 
The target population was practicing CRNAs that are current members of the 
Mississippi Association of Nurse Anesthetists (MANA). MANA members include 500-
600 CRNAs working in a variety of different clinical settings throughout the state of 
Mississippi. Inclusion criteria was limited to licensed CRNAs currently practicing in the 
perioperative setting in Mississippi and participants must be at least 18 years of age. All 
other survey participants were excluded. 
Setting 
The DNP project utilized MANA membership. Data was collected from CRNAs 
licensed and working in the state of Mississippi, and results from the project were 
disseminated to the association for the purpose of improving patient outcomes. The 
MANA membership reflects CRNAs working in settings covering the full spectrum of 
clinical practice, including rural hospitals, ambulatory surgery centers, office based 
practice, as well as trauma centers throughout Mississippi. 
Design 
The DNP project assessed the current practice of CRNAs using dexamethasone 
for the prevention of PONV. MANA members were sent a short presentation outlining 
current guidelines set forth by the Society for Ambulatory Anesthesia (Gan et al., 2014) 
as well as supporting evidence-based on the review of literature. The educational 
presentation can be found in Appendix C. In addition, a link to a short survey was 
provided. Questions covered familiarity with the current guidelines set forth by the 
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Society for Ambulatory Anesthesia, preferred dosage (4mg, 8mg, other), preferred timing 
of administration (pre-induction, during or immediately after induction, immediately 
before emergence), whether they felt their current practice is effective, and willingness to 
change current practice if provided with an evidence-based alternative. Demographic data 
including sex, age, and years of practice was also gathered. The survey tool can be found 
in Appendix D. 
Survey data remained completely anonymous, and was only used for study 
purposes and analysis based on the stated target outcomes. Participation in the survey was 
completely voluntary and posed no risk to those choosing to do so. In addition, 
participants were provided with an educational opportunity aimed at optimizing their 
current practice. Subjects were chosen based on their willingness to participate using a 
convenience sample, this type of sampling allowed for access to a large number of 
practicing CRNAs in Mississippi and helped to maximize survey participation. Survey 
responses were collected using a password protected account provided by the online 
survey tool Qualtrics. Survey data was stored on a personal computer for the purposes of 
analysis and interpretation. The personal computer and its contents were password 
protected for the duration of the study, after which survey data was removed. At no time 
was identifiable information collected or stored for the purposes of the DNP project. 
Following data analysis, MANA was presented with findings and 
recommendations based on current guidelines set forth by SAMBA and supporting 
evidence to help improve patient outcomes if indicated by the results of the survey. 
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Procedure 
Following University of Southern Mississippi (USM) Institutional Review Board 
(IRB) approval, an electronic survey developed using the online tool Qualtrics provided 
by USM, and an electronic presentation outlining the current guidelines set forth by 
SAMBA (Gan et al., 2014) and supporting evidence was emailed to members of MANA. 
Procedures for data collection were as follows: 
1. An email containing two anonymous links was sent to all MANA members 
through MANA's membership email list. The first link allowed participants to 
view the electronic presentation outlining current literature and guidelines. 
The second link provided access to the electronic survey administered through 
the online survey tool Qualtrics. 
2. Participants were then asked to review the electronic presentation first, 
followed by completion of the electronic survey. Participants were given two 
weeks to complete the survey starting from the date the email was delivered. 
A reminder email was sent when one week remained in the survey period. 
3. After the survey period of two weeks had passed, the survey was closed. 
4. Data was then compiled and analyzed.   
Data Analysis 
Results were analyzed using descriptive statistics utilizing frequency tables for the 
purpose of determining if and how CRNAs within MANA were using dexamethasone for 
the purpose of preventing PONV. Knowing how CRNAs administer dexamethasone can 
help to guide future efforts aimed at educating CRNAs on preventing PONV. Results 
were compared to the most recent guidelines set forth by SAMBA and the supporting 
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evidence found within the review of literature for the purpose of guiding 
recommendations for future practice. 
Ethics 
The electronic questionnaire was completely anonymous and completed on a 
voluntary basis. Participation in this survey and its findings posed no risk to participants, 
and analysis of the data focused on optimization of current practice. Any change in 
practice or patient care related to the findings of this DNP project was determined by the 
anesthesia providers. 
Assumptions 
The main assumption was that the anesthesia providers surveyed view PONV as 
an important and modifiable complication following surgery. It was also assumed that 
patient outcomes at the facilities staffed by the CRNAs belonging to MANA can be 
improved with the optimization of dexamethasone administration relating to PONV. 
Resource Requirements 
Few resources were required for this DNP project. Those required included the 
University of Southern Mississippi library, access to a computer, access to the internet, 
and related books. 
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CHAPTER IV – ANALYSIS OF DATA 
Results 
During the two week survey period, 36 responses were recorded using the online 
survey tool Qualtrics. Of those 36 responses, 24 reported they were currently licensed 
and practicing CRNAs and 12 reported they were not. Assuming a total membership of 
600 as reported by MANA, this represents a total response rate of 6%. For the purposes 
of this project, only the 24 participants indicating they were licensed and practicing 
CRNAs were used for analysis representing a useable response rate of 4%. 14 of the 
participants were male (58.33%), while the remaining 10 participants indicated they were 
female (41.67%). Participants ranged in age from 30 to 60 or greater years old, with the 
majority of participants (45.83%) reporting between 40 and 49 years old as shown in 
Table 2. Regarding work experience, the majority of participants (58.34%) reported 
having worked for 10 years or less as a CRNA as shown in Table 3. 
Table 2 Question 2 
Answer % n 
18-29 0.00% 0 
30-39 33.33% 8 
40-49 45.83% 11 
50-59 8.33% 2 
60 or above 12.50% 3 
Total 100% 24 
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Table 3 Question 4 
Answer % n 
0-5 29.17% 7 
6-10 29.17% 7 
11-15 20.83% 5 
16-20 8.33% 2 
20 or more 12.50% 3 
Total 100% 24 
 
Question 5 
When asked about their previous knowledge of the guidelines proposed by 
SAMBA for the prevention of PONV, all participants reported being at least slightly 
familiar with the guidelines, with 12 participants (50%) being either Very familiar or 
Extremely familiar with the guidelines. Six (25.00%) reported being Moderately familiar, 
while six (25.00%) reported being Slightly familiar. No participants reported being Not 
familiar at all with the guidelines. 
Table 4 Question 5 
Answer % n 
Extremely familiar 16.67% 4 
Very familiar 33.33% 8 
Moderately familiar 25.00% 6 
Slightly familiar 25.00% 6 
Not familiar at all 0.00% 0 
Total 100% 24 
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Question 6 
When asked how often they administer dexamethasone to prevent PONV, all 
participants reported administering dexamethasone at least Sometimes, with 19 
participants (79.17%) saying they administer it either Most of the time or Always to help 
prevent PONV. Two (8.33%) reported About half the time, and three (12.50%) reported 
Sometimes. No participants reported administering dexamethasone Never. 
Table 5 Question 6 
Answer % n 
Always 29.17% 7 
Most of the time 50.00% 12 
About half the time 8.33% 2 
Sometimes 12.50% 3 
Never 0.00% 0 
Total 100% 24 
 
Question 7 
Participants were asked about their preferred dosage of dexamethasone for the 
prevention of PONV prior to viewing the presentation. 15 participants (62.50%) reported 
4 mg was their preferred dosage, reflecting the guidelines set forth by SAMBA on PONV 
prevention. Eight participants (33.33%) reported 8 mg was their preferred dosage for 
preventing PONV. One participant (4.17%) chose Other, allowing them to write in their 
preferred dosage of 12 mg. 
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Table 6 Question 7 
Answer % n 
8mg 33.33% 8 
4mg 62.50% 15 
Other (mg) 4.17% 1 
I don't administer dexamethasone to prevent PONV 0.00% 0 
Total 100% 24 
 
Question 8 
Participants were asked what their preferred dosage of dexamethasone was after 
having viewed the provided presentation. 20 participants (83.33%) reported 4 mg would 
now be their preferred dosage. Three participants (12.50%) reported they would continue 
to administer 8 mg, and one participant (4.17%) reported they would continue to 
administer their preferred dosage of 12 mg. This represents an increase of five 
participants (20.83%) reporting they will now be administering the recommended dosage 
of 4-5 mg of dexamethasone as outlined in the guidelines set forth by SAMBA. This 
finding suggests that CRNAs are willing to change their current practice if provided with 
an evidence-based alternative. 
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Table 7 Question 8 
Answer % n 
8mg 12.50% 3 
4mg 83.33% 20 
Other (mg) 4.17% 1 
I don't administer dexamethasone to prevent PONV 0.00% 0 
Total 100% 24 
 
Question 9 
When participants were asked during which phase of anesthesia they preferred to 
administer dexamethasone to prevent PONV, 20 (83.34%) reported either Pre-induction 
or During or immediately after induction. This finding reflects the recommendations in 
the guidelines set forth by SAMBA, suggesting that the majority of CRNAs administer 
dexamethasone to prevent PONV based on the best evidence currently available. The 
remaining four participants (16.67%) reported administering dexamethasone During 
maintenance of anesthesia to prevent PONV. 
Table 8 Question 9 
Answer % n 
Pre-induction 4.17% 1 
During or immediately after induction 79.17% 19 
During maintenance of anesthesia 16.67% 4 
Immediately before or during emergence 0.00% 0 
After emergence 0.00% 0 
I don't administer dexamethasone to prevent PONV 0.00% 0 
Total 100% 24 
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Question 10 
When participants were asked about how effective they feel dexamethasone is at 
preventing PONV, seven (29.17%) responded that they feel dexamethasone is 
Moderately effective, 13 (54.17%) feel it is Very effective, and four (16.67%) feel it is 
Extremely effective. No participants responded that they feel dexamethasone is Not 
effective at all at preventing PONV. This finding suggests that CRNAs trust 
dexamethasone as an effective preventative treatment for PONV, and administer it for 
this purpose. 
Table 9 Question 10 
Answer % n 
Extremely effective 16.67% 4 
Very effective 54.17% 13 
Moderately effective 29.17% 7 
Slightly effective 0.00% 0 
Not effective at all 0.00% 0 
Total 100% 24 
 
Question 11 
When participants were asked to rate their willingness to administer 
dexamethasone by using the technique as described in the provided presentation based on 
the guidelines set forth by SAMBA, 23 (95.83%) responded by saying they were either 
Very willing or Extremely willing to do so. One (4.17%) said they were Moderately 
willing, and no participants responded they were Not willing at all. This finding suggests 
either CRNAs were already administering dexamethasone to prevent PONV using the 
technique as described in the provided presentation, or CRNAs are willing to change their 
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current practice when provided with an evidence-based alternative aimed at optimizing 
patient outcomes. 
Table 10 Question 11 
Answer % n 
Extremely willing 45.83% 11 
Very willing 50.00% 12 
Moderately willing 4.17% 1 
Slightly willing 0.00% 0 
Not willing at all 0.00% 0 
Total 100% 24 
 
Discussion 
Using the target outcomes of this project as a guide, interpretation of the survey 
results reveals several noteworthy findings. By assessing current practice among CRNAs, 
it is clear that CRNAs do administer dexamethasone for the purpose of preventing 
PONV. Question six shows that 19 participants (79.17%) administer dexamethasone 
either Most of the time or Always to help prevent PONV. Question seven shows that 15 
participants (62.50%) administer 4 mg of dexamethasone when given to prevent PONV. 
Question nine shows that 20 participants (83.34%) reported either Pre-induction or 
During or immediately after induction as their preferred time to administer 
dexamethasone to prevent PONV. These findings not only suggest that CRNAs 
administer dexamethasone to prevent PONV, but also that the majority of CRNAs 
surveyed do so using the technique found in the guidelines set forth by SAMBA, which 
suggests giving 4 mg of dexamethasone pre-induction, during induction, or immediately 
after induction of anesthesia. 
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Further analysis of the survey results gives insight into how willing CRNAs are to 
change their current practice as well. Question seven and question eight show a 
difference exists in CRNAs’ preferred dosage of dexamethasone when comparing 
responses prior to viewing the provided presentation and after viewing the presentation. 
In accordance with the guidelines set forth by SAMBA, 15 participants (62.50%) gave 4 
mg of dexamethasone prior to viewing the presentation. After viewing the presentation, 
20 participants (83.33%) reported 4 mg would be their preferred dosage of 
dexamethasone for preventing PONV. This finding shows an increase of 5 participants 
(20.83%) reporting they will now administer 4 mg of dexamethasone as suggested in the 
guidelines set forth by SAMBA. Question 11 shows 23 participants (95.83%) were 
willing to administer dexamethasone following the technique outlined in the presentation 
and based on the guidelines set forth by SAMBA. The responses to questions seven, 
eight, and eleven suggest that the majority of CRNAs surveyed are willing to change 
their current practice when provided with an evidence-based alternative aimed at 
optimizing patient outcomes. 
Limitations 
The survey for this project was completed on a voluntary basis, and relied 
completely on the CRNAs’ willingness to do so. As such, it is hard to determine whether 
the sample is representative of the general population, especially given the small sample 
size (n=24) and low total response rate of 6%. While the findings of this project offer 
some insight for current CRNA practice, the results are only applicable to the sample 
surveyed. Based on the small sample and low response rate, it is also difficult to 
determine whether a significant level of correlation exists between survey questions when 
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analyzing responses, allowing only for the use of descriptive statistics. This project also 
does not take into account how CRNAs use dexamethasone in tandem with other 
prophylactic anti-nausea treatments, or how dexamethasone administration may be 
affected by alternative measures or disease processes. 
Future Practice 
The implications of this project are based on the major findings of the survey 
results; a majority of CRNAs surveyed administer dexamethasone in accordance with the 
guidelines set forth by SAMBA, and a majority of CRNAs surveyed are willing to 
change their current practice if presented with an evidence-based alternative aimed at 
optimizing patient outcomes. These findings suggest CRNAs are receptive to the most 
current evidence-based practices, and are willing to integrate new techniques into their 
own practice when trying to optimize patient outcomes. Each of these attributes is 
important in ensuring the best possible care is provided to each patient. 
While the overall findings are positive, there are several responses indicating a 
reluctance to change current practice based on the presentation and evidence provided. It 
is impossible to determine reasons for this with the current data set, but future studies can 
do so using more in depth surveys as well as sampling from a larger population. By 
reaching out to other state nurse anesthesia associations, as well as student registered 
nurse anesthetists, a much larger sample can be surveyed in the hope of creating a more 
generalizable data set. Future studies should also take into account other aspects of the 
guidelines set forth by SAMBA, as dexamethasone is only one small piece of the puzzle 
when trying to prevent PONV. 
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This capstone project utilized the first four steps outlined by Rosswurm and 
Larrabee (1999) in their Model for Change to Evidence-Based Practice: assessing the 
need for change through the literature review and survey, linking the need with specific 
interventions and outcomes based on the current guidelines, compiling the evidence 
through analysis of the current literature and survey results, and creating a plan for 
changing the current practice by providing an educational presentation outlining the 
current literature and guidelines. Future researchers should aim to utilize the final two 
steps in Rosswurm and Larrabee’s process: implementing and evaluating the change and 
merging the change with current standards. A retrospective chart review focused on 
PONV and dexamethasone administration trends within a facility or region would 
provide valuable information allowing for the evaluation of the change in practice, and 
whether the current guidelines set forth by SAMBA should be made standard of practice 
within the population being studied. 
Conclusion 
A review of the literature has shown that PONV is a significant contributing 
factor to extended recovery times and unwanted hospital admissions following 
ambulatory surgery. The findings of this project suggest the majority of CRNAs surveyed 
are active participants in utilizing the most current evidence-based practice, and are 
willing to integrate new techniques into their own practice with the goal of optimizing 
patient outcomes. By continuing to do so, CRNAs are able to play an integral role in 
expanding clinical knowledge and improving patient outcomes. While the results of this 
project are encouraging, there is certainly a need for future studies to help improve our 
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understanding of how CRNAs currently use the resources available to them when trying 
to prevent PONV. 
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APPENDIX E – DNP Essentials 
 
DNP Essentials Capstone relation to DNP Essentials 
DNP Essentials I – Scientific 
underpinnings for practice 
This DNP project is centered on the most 
current evidenced based guidelines for 
using dexamethasone to prevent PONV. 
These guidelines were created through 
multidisciplinary collaboration, and are 
supported by peer-reviewed research. 
DNP Essentials II – Organizational and 
systems leadership for quality 
improvement and systems thinking 
PONV is a frequent and disruptive part of 
the perioperative experience. This DNP 
project is aimed at improving patient 
outcomes through the optimized dosage 
and timing of dexamethasone 
administration for preventing PONV and 
was designed as a quality improvement 
project. 
DNP Essentials III – Clinical 
scholarship and analytical methods for 
evidence-based practice 
By using Rosswurm and Larrabee’s 
Model for Change to Evidence-Based 
Practice, this DNP project uses a 
framework allowing for its use in different 
settings for the purpose of assessing 
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practice and quality improvement to better 
anesthesia practice 
DNP Essentials IV – Information 
systems or technology and patient care 
technology for the improvement and 
transformation of health care 
This DNP project required the use of 
electronic databases to perform the review 
of literature. An electronic survey and 
educational presentation were also created 
for the purpose of gathering data and 
educating CRNAs on the most current 
guidelines set forth by SAMBA 
DNP Essentials V – Healthcare policy 
for advocacy in healthcare 
Through its collaboration with MANA 
and dissemination of results to MANA 
members, this DNP project has the 
potential to influence future practice and 
policy across the state of Mississippi. 
DNP Essentials VI – Interprofessional 
collaboration for improving patient and 
population health outcomes 
Through the education of CRNAs 
regarding dexamethasone’s use as an anti-
emetic, the CRNAs will be better able to 
share their knowledge of PONV 
prevention with other healthcare 
professionals in the perioperative setting. 
This shared knowledge will allow for a 
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more seamless transition of care through 
the perioperative period. 
DNP Essentials VII – Clinical 
prevention and population health for 
improving the nation’s health 
PONV can cause increased PACU times 
and delayed recovery following surgical 
procedures. This DNP project was aimed 
at using dexamethasone prophylactically 
to prevent PONV from occurring. 
DNP Essentials VIII – Advanced 
Nursing Practice 
This DNP project was ultimately aimed at 
evaluating one’s current practice and 
utilizing the most current evidence-based 
literature to make clinical decisions for 
the purpose of improving patient 
outcomes. 
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